Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal trivalent antimony for cutaneous leishmaniasis
IRCT20250202064600N1Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Wound size, Induration and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20250202064600N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250202064600N1.